Next-Generation Gynecological Cancer Diagnostics Market Growth and Forecast Report, 2030

NEW YORK - Feb. 5, 2024 - PRLog -- The next-generation gynecological cancer diagnostics market is set to reach USD 5,135 million by 2030, powering at a rate of 10% in the years to come. This is because of the increasing prevalence of changes in lifestyle and obesity in women, gynecological malignancies, growing cases of menopause issues, and the rising incidence of diabetes.

The next-generation sequencing category dominated the industry in 2022, and it will continue like this in the years to come. This is because of the possibility of NGS for identifying genetic alteration, actionable with targeted therapy.

NGS has a possibility of 33.4% in recognizing gynecologic cancers and a high clinical action rate. With the inordinate clinical utility of NGS, testing also can improve survival for people received targeted treatment.

The uterine cancer category was the leader of the pack, with over 30%, in 2022, and it is will maintain its dominance in the years to come as well. This has a lot to do with the increasing cases of uterine cancer globally, as a result of the rising elderly women populace, increasing menopause matters after 55, the growing frequency of high sugar levels and BP, rising conditions of overweight or obesity and high estrogen levels.

Browse detailed report analysis on Next-Generation Gynecological Cancer Diagnostics Industry Growth and Forecast Report, 2030 (https://www.psmarketresearch.com/market-analysis/next-gen...)

North American next-generation gynecological cancer diagnostics market dominated the industry with a share of over 40%, in 2022, and it will grow at a healthy rate in the future. The main reason for this is the increasing cases of gynecological and cervical malignancies.

The increasing cases of gynecological cancer cases in women, all over the globe has a positive impact on next-generation gynecological cancer diagnostics solutions, and this trend will continue in the near future as well.